Chembio Diagnostics Inc (NASDAQ:CEMI) Announces Results Of Its Latest Clinical Trial

The stock of Chembio Diagnostics Inc (NASDAQ:CEMI) closed at $7.70 gaining 0.65% in yesterday’s trading session. Chembio Diagnostics has already completed its most recent clinical trial that targeted evaluating its DPP® HIV-Syphilis System. At the moment, it has plans underway to file for a Pre-Market Approval (PMA) submission. That will of course be with the Food and […]